CEP-28122 is primarily utilized in the field of medical research, particularly in oncology. It functions as a potent and selective inhibitor of ALK (anaplastic lymphoma kinase), which is a protein involved in the development of certain types of cancers. By inhibiting ALK, CEP-28122 helps to block the signaling pathways that promote the growth and survival of cancer cells. This makes it a valuable tool in preclinical studies aimed at understanding the role of ALK in cancer progression and in the development of targeted therapies for ALK-positive cancers, such as non-small cell lung cancer and neuroblastoma. Researchers use CEP-28122 to explore its potential efficacy and to optimize treatment strategies for patients with ALK-driven malignancies.